Emergency HF Mortality Risk Grade (EHMRG) Calculator

Clinical calculation support · Verify results before clinical use

Patient presentation

Use values available at the initial emergency department assessment.

EHMRG7-day risk
Arrived by ambulance / EMS?

Enter to one decimal place: ≤3.9, 4.0–4.5, or ≥4.6 mmol/L.

Troponin above the local upper limit of normal?
Active cancer / malignancy?
Taking metolazone at home?

If unknown or metolazone is not used locally, the original calculator suggests selecting No; interpret this variable cautiously.

About the EHMRG

The Emergency Heart Failure Mortality Risk Grade (EHMRG) is a prognostic model developed to estimate short-term mortality among patients presenting to an emergency department with acute heart failure. EHMRG7 predicts 7-day mortality; a related EHMRG30-ST model includes ST-segment depression to estimate 30-day mortality.

Variables and point rules used here

VariablePoint rule in this implementation
Age+2 × age in years
EMS arrival+60 if Yes
Systolic BP−1 × mmHg
Heart rate+1 × beats/min
Oxygen saturation−2 × percentage
Creatinine+20 × mg/dL
Potassium≤3.9: +5; 4.0–4.5: 0; ≥4.6: +30
Troponin above ULN+60 if Yes
Active cancer+45 if Yes
Home metolazone+60 if Yes
Constant+12

Risk bands and 7-day mortality

GradeScore boundaryValidation mortality
1 · Very low≤ −49.00.0%
2 · Low−49.0 to −15.80.0%
3 · Intermediate−15.8 to 18.00.6%
4 · High18.0 to 56.61.9%
5 · Very high>56.63.9%

These five bands and rates reflect the prospective validation cohort reported by Lee and colleagues. They should not be interpreted as universal, individually calibrated probabilities.

Clinical disclaimer: This educational calculator is not a substitute for clinical assessment, local protocols, or specialist judgment. Verify inputs, units, and applicability before use. The score alone must not determine discharge, admission, or monitoring level. The original point implementation is retained from the supplied file; confirm its coefficients and boundaries against the primary model documentation before clinical deployment.